Aurinia Pharmaceuticals IncAurinia Pharmaceuticals IncAurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

No trades
See on Supercharts
Market capitalization
‪737.55 M‬USD
−0.55USD
‪−78.02 M‬USD
‪175.51 M‬USD
‪127.86 M‬
Beta (1Y)
1.95

About Aurinia Pharmaceuticals Inc

CEO
Peter S. Greenleaf
Headquarters
Edmonton
Employees (FY)
300
Founded
1993
ISIN
CA05156V1022
FIGI
BBG000BCRJM5
Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of AUPH is 5.04 USD — it has decreased by 1.18% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aurinia Pharmaceuticals Inc stocks are traded under the ticker AUPH.
Aurinia Pharmaceuticals Inc is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Aurinia Pharmaceuticals Inc has a max estimate of 15.00 USD and a min estimate of 8.00 USD.
AUPH earnings for the last quarter are −0.09 USD whereas the estimation was −0.17 USD which accounts for 46.15% surprise. Estimated earnings for the next quarter are −0.16 USD. See more details about Aurinia Pharmaceuticals Inc earnings.
Aurinia Pharmaceuticals Inc revenue for the last quarter amounts to ‪54.52 M‬ USD despite the estimated figure of ‪38.44 M‬ USD. In the next quarter revenue is expected to reach ‪45.00 M‬ USD.
Yes, you can track Aurinia Pharmaceuticals Inc financials in yearly and quarterly reports right on TradingView.
Like other stocks, AUPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aurinia Pharmaceuticals Inc stock right from TradingView charts — choose your broker and connect to your account.
AUPH reached its all-time high on Nov 3, 2021 with the price of 33.97 USD, and its all-time low was 1.00 USD and was reached on Sep 10, 2012.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 300.00 employees. See our rating of the largest employees — is Aurinia Pharmaceuticals Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aurinia Pharmaceuticals Inc EBITDA is ‪−71.47 M‬ USD, and current EBITDA margin is −40.83%. See more stats in Aurinia Pharmaceuticals Inc financial statements.